Nadarajah Sreeharan

Prof Sreeharan currently holds Visiting Professorships at King’s College, London & University of Jaffna, Sri Lanka and acts as a Consultant to the Biotechnology Industry. He graduated from the University of Colombo in 1970 with 1st class honours and had his initial postgraduate training at the University of Peradeniya obtaining the MD (Colombo) and subsequently completed the MRCP and a PhD in Cardiovascular physiology at the British Heart Foundation Department of Cardiovascular Studies in Leeds, UK. He is a Fellow of the Royal College of Physicians of London. Edinburgh and Glasgow and of the American College of Physicians.

He was formerly the Foundation Professor of Medicine at the University of Jaffna and held Visiting Professorships at the University of Alberta, Canada, University of Surrey, UK and the UITM Medical Faculty in Kuala Lumpur, Malaysia. During his tenure as Senior Vice President & European Medical Director in the Global R&D organisation at GlaxoSmithKline, he chaired an integrated medical department based across the European countries with oversight for the research & development of new medicines across multiple therapeutic areas. He led teams that developed the first non-ergot selective dopamine agonist for Parkinson’s Disease (ropinirole), the first beta blocker for Heart Failure (carvedilol), an insulin sensitizer for Type 2 Diabetes (rosiglitazone), a combination steroid/LABA for COPD (Seretide), an SSRI for depression/anxiety spectrum (paroxetine), a 5 alpha reductase inhibitor for BPH (dutasteride) and a topoisomerase inhibitor for Ovarian and Small cell Lung cancers (topotecan).

As an Officer of the Board of Examiners in Pharmaceutical Medicine at the Royal College of Physicians, an advisor to the National Board of Medical Examiners in the USA and a faculty to the Scholars in Clinical Science Program at the Harvard Medical School, he facilitated the international development of Pharmaceutical Medicine as an accredited medical specialty. Prof Sreeharan has authored several publications and book chapters on atrial receptors, endothelium dependent relaxation factor, drug development, clinical cardiology and tropical medicine.

Primary Affiliation: Institute of Pharmaceutical Sciences - London , United Kingdom

Specialties:

Additional Specialties:

Research Interests: